Breaking News

Dollar Tree Agrees to Buy Family Dollar for $74.50 a Share
Tweet TWEET

Merck, Sangamo to Gain From $70 Million Boost in AIDS Cure Hunt

Merck & Co., Sangamo Biosciences Inc. (SGMO) and researchers searching for an AIDS cure will benefit from grants worth more than $70 million as the U.S. government strives for an end to the world’s deadliest infectious disease.

The National Institutes of Health awarded more than $14 million a year for five years to three groups of scientists to advance research aimed at curing AIDS, the Bethesda, Maryland- based agency said in a statement on its website today.

The biggest grant, of $6.3 million in the first year, will go to a group of 19 laboratories led by David Margolis, a professor of medicine at the University of North Carolina in Chapel Hill. He’s working with Merck to develop a line of drugs aimed at purging HIV from cells where it hides out, evading AIDS treatments and condemning patients to a lifetime of popping pills.

“The NIH has said for a while that it’s one of the top three priorities in AIDS research,” Margolis said in a telephone interview. “Now they’re putting their money where their mouth is.”

About 2.6 million people became infected with HIV in 2009, and more than 1.8 million people died with AIDS-related causes, according to the Joint United Nations Programme on HIV/AIDS.

The NIH awarded $4.2 million to scientists led by Steven Deeks at the University of California, San Francisco, who are also working with Merck, and $4.1 million to researchers led by Keith Jerome at the Fred Hutchison Cancer Research Center in Seattle, who are working with Richmond, California-based Sangamo.

To contact the reporter on this story: Simeon Bennett in Singapore at sbennett9@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.